Every UAE pharmaceutical registration stands or falls on its dossier. The Emirates Drug Establishment (EDE) reviews files in the Common Technical Document (CTD) format, and the difference between a smooth review and a long one is almost always preparation. This checklist sets out what a UAE submission needs, module by module, and where files most often fall short.
Why the CTD format matters in the UAE
Under the UAE pharmaceutical law in force from 2025, the EDE is the federal authority for product classification, product registration and marketing authorisation, manufacturing site registration, and import and export permits. These functions transferred from the Ministry of Health and Prevention (MOHAP). Registration files are compiled and assessed in the CTD structure, the same five-module format used by major agencies worldwide.
The order of operations matters as much as the format. A first-time foreign manufacturer registers the manufacturing site first (a one-off step per site), obtains a product classification where the category is unclear, and then registers each product. The dossier described below belongs to that final step, and it carries the weight of the review. Pharmaceutical registration timelines vary by pathway and are subject to authority response times, so the completeness of the file is the variable you control.
We compile and submit these files as part of our pharmaceutical product registration service, and the checklist below reflects what a submission-ready dossier contains.
The five modules, as a checklist
Work through the modules in order. Each one answers a different question for the assessor.
Module 1: administrative and regional information
Application forms, letters of authorisation appointing your UAE local representative, the certificates and licences relied on in the application, and the proposed labels, artwork, and patient leaflets. Prepare labels and leaflets in English and Arabic from the start, not as an afterthought.
Module 2: summaries and overviews
The quality overall summary plus the nonclinical and clinical overviews. These are the first pages an assessor reads, so they should present the product accurately and point cleanly to the data in Modules 3 to 5.
Module 3: quality
Full chemistry, manufacturing, and controls data for the drug substance and the drug product: composition, manufacturing process, specifications, analytical methods, and stability data that supports the shelf life claimed on the artwork.
Module 4: nonclinical study reports
Pharmacology, pharmacokinetics, and toxicology reports. For generic products this module typically leans on published data and the established profile of the active substance.
Module 5: clinical study reports
The clinical data supporting efficacy and safety. For generics, this is where the bioequivalence (BE) study against the innovator product sits. BE data must be included in the dossier; no local UAE BE studies are required.
UAE-specific points to check
A dossier that satisfies the CTD headings can still stumble on UAE-specific expectations. Run these checks before anything is submitted.
UAE points that decide the review
- Dossiers, labels, and leaflets must be available in English and Arabic
- Generics: a BE study against the innovator product must be included in the dossier; no local UAE BE studies are required
- Manufacturing site registration comes first and is a one-off step per site
- Product classification is the first step where the category is unclear
- Site registration and product registration certificates are each valid for 5 years
- EDE inspections of foreign sites are at the authority's discretion, not guaranteed
The last point is worth planning around. Because a physical inspection of a foreign site is discretionary, the documentary evidence of the site's GMP standing does more work in the file than manufacturers expect. Prepare the quality documentation as if no inspector will ever visit the site, because there may never be one.
Common gaps that slow files down
Across the dossiers we review, the same gaps recur. None of them are exotic, and all of them cost weeks.
- Arabic labelling treated as a post-approval task, when it belongs in Module 1 from the first submission
- A BE study run against a comparator that is not the innovator product
- Product registration filed before the manufacturing site registration is in place
- Classification skipped on borderline products, so the file is built for the wrong pathway
- Stability data that does not support the shelf life claimed on the artwork
Each of these produces a deficiency letter, and each deficiency round adds calendar time that is subject to authority response times. A pre-submission gap check is cheaper than any of them.
Frequently asked questions
Do UAE pharmaceutical submissions follow the CTD format?
Do generic products need local UAE bioequivalence studies?
What languages must the dossier and labelling be in?
How long is a UAE product registration valid?
Explore our product registration service
This checklist is general information, not regulatory or legal advice. Requirements evolve as the EDE develops its processes; confirm current rules with the relevant authority or contact our team before acting on a specific file.